DOASENSE - Resources - Pioneering Point-of-Care Testing for DOACs

Go to content
Publications on DOASENSE DOAC Dipstick

Resources

Here you can find publications and other resources related to the DOASENSE products.

Please note that our products are for health care professional use only!

DOASENSE IFU
DOASENSE Training

Recent Publications

  • National Institute for Health and Care Excellence (NICE):
    DOAC Dipstick for detecting direct oral anticoagulants
    Medtech innovation briefing [MIB248], Published: 02 February 2021 [read HERE]

  • ANTICOAGULATION FORUM
    Reversal and Treatment Strategies for DOAC-Related Bleeding
    Updated 01-2021 [read HERE]

  • Harenberg J, Martini A, Du S, Krämer S, Weiss C, Hetjens S:
    Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine
    Clinical and Applied Thrombosis/Hemostasis, Volume 27: 1-6, 2021 [read HERE]

  • Meyer T, Werner CJ, Kammer S, Dafotakis M:
    DOAC-Dipstick-Test: Therapieentscheidungshilfe beim ischämischen und hämorrhagischen Schlaganfall
    ANIM 2021 [view poster (in German)]

  • Harenberg J, Loesel F, Douxfils J, Elalamy I, Bauersachs R, Beyer-Westendorf J, Crowther M, Verhamme P, Hetjens S, Weiss C:
    Comparison of visual versus reader results of the point of care test of direct oral anticoagulants from urine samples
    ISTH 2020, Poster PB0590 [view poster]

  • Harenberg J, Bauersachs R, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Hetjens S, Verhamme P, Weiss C:
    Inter-centre and inter-observer agreement of determination of DOACs in urine samples of patients by means of DOAC Dipstick test
    ISTH 2020, Poster PB0525 [view poster]

  • Harenberg J, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Verhamme P, Bauersachs R, Hetjens S, Weiss C:
    Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine — A Multicenter Trial
    Thromb Haemost 2020; 120(01): 132-140
    [Free open access download HERE]


  • Favaloro EJ, Lippi G:
    The Pointy End of Point-of-Care Testing for Direct Oral Anticoagulants
    Thromb Haemost 2020;120:11–13. [download editorial]

  • Harenberg J, Schreiner H, Hetjens S, Weiss C:
    Detecting Anti-IIa and Anti-Xa Direct Oral Anticoagulant (DOAC) Agents in Urine using a DOAC Dipstick.
    Semin Thromb Hemost 2019; 45: 275–284
    [Free open access download HERE]

  • Robert C. Gosselin, Dorothy M. Adcock, Jonathan Douxfils:
    An update on laboratory assessment for direct oral anticoagulants (DOACs)
    Int J Lab Hematol. 2019;41(Suppl. 1):33–39 [article]

  • Brigitte Söllner:
    DOAC Dipstick: Einfacher Nachweis von direkten oralen Antikoagulanzien aus dem Urin
    Perfusion 2/2019: 54-56  (in German) [download article]

  • Robert C. Gosselin, Dorothy M. Adcock, Shannon M. Bates, Jonathan Douxfils, Emmanuel J. Favaloro, Isabelle Gouin-Thibault, Cecilia Guillermo, Yohko Kawai, Edelgard Lindhoff-Last, Steve Kitchen:
    International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
    Thromb Haemost 2018; 118(3): 437-450  [ICSH Guidelines]

  • J. Harenberg, S. Hetjens, R. Schreiner, R. Krämer, C. Weiss:
    DOAC Dipstick for determination of absence or presence of direct oral anticoagulants and creatinine in urine
    Res Pract Thromb Haemost 2018; 2(Suppl. 1): PB242 [Poster]

  • J. Harenberg, U. Warttinger, S. Hetjens, R. Schreiner, C. Giese, H.-J. Roth, R. Krämer, C. Weiss:
     Reliability and validity of point-of-care tests taken from urine samples of patients on therapy with Apixaban, Rivaroxaban and Dabigatran
    Res Pract Thromb Haemost 2017; 1(Suppl1): PB454 [Poster]

  • Harenberg J, Ahrens I, Bauersachs R, Haas S, Koscielny J, Kraemer R, Lindhoff-Last E, Prochaska J, Schellong S, Spannagl M, Wild P, Beyer-Westendorf J:
    A qualitative point of care test to assess anticoagulant activity in urine samples of patients treated with non-vitamin K antagonist oral anticoagulants - a german consensus.
    J Thromb Haemost 2015; 13(Suppl 2): 636-637 (PO356-Tue)

  • Harenberg J, Du S, Wehling M, Zolfaghari S, Weiss C, Krämer R, Walenga J:
    Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
    Clin Chem Lab Med. 2016 Feb 1; 54(2): 275-83

  • Favaloro EJ, Lippi G:
    Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors.
    Semin Thromb Hemost. 2015 Mar; 41(2): 208-27

  • Harenberg J, Du S, Krämer R, Weiss C, Krämer R, Wehling M:
    Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants.
    Semin Thromb Hemost. 2015 Mar; 41(2): 228-36

  • Harenberg J, Du S, Krämer R, Weiss C:
    Correctness of the identification by patients of colour of urine samples obtained a point of care test for dabigatran and rivaroxaban
    J Thromb Haemost 2013, 11 (Suppl 1) PB 4.45-05 [read HERE]

  • Harenberg J, Krämer S, Du S, Weiss C, Krämer R:
    Concept of a point of care test to detect new oral anticoagulants in urine samples.
    Thromb J. 2013 Aug 1; 11(1):15

Product Brochures


  • Brochure: DOASENSE Product Suite  [Download]

Slide Sets


  • Speaker slide set: DOAC Dipstick basics [Download]

Related Information

  • Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss G-BA) decided to expand the guideline for care of hip fractures to include regulations on testing for DOACs.
    The G-BA also mentions the DOASENSE DOAC Dipstick as suitable DOAC test:
    "For all four common DOAKs, a urine dipstick test with colour coding is also available, which indicates with very high reliability whether relevant active substance concentrations are present in the urine".

    Richtlinie zur Versorgung der hüftgelenknahen Femurfraktur: Ergänzung der Regelungen zur SOP „Umgang mit gerinnungshemmender Medikation“ [read HERE in German]

  • Read the interview with German trauma surgeon Dr. Caspers, who emphasizes the importance of rapid point-of-care testing on DOACs in cases of fractures near the hip joint: [read in German or the English convenience translation]
    Management & Krankenhaus 3/2021


“When every minute counts” is best illustrated by this article, evidencing the importance of rapid treatment and therefore DOAC testing for ischemic patients.
“Among patients aged 65 years or older with acute ischemic stroke, who were treated with tissue plasminogen activator, shorter door to needle time were associated with lower all-cause mortality and lower all-cause readmission at 1 year. The findings support efforts to shorten time to thrombolytic therapy":

  • Man S, Xian Y, Holmes DN, Matsouaka RA, Saver JL, Smith EE, Bhatt DL, Schwamm LH, Fonarow GC:
    Association Between Thrombolytic Door-to-Needle Time and 1-YearMortality and Readmission in Patients With Acute Ischemic Stroke
    JAMA. 2020;323(21):2170-2184. DOI: 10.1001/jama.2020.5697  [    read HERE]

Videos

Video material related to the DOASENSE product suite:

(Please also visit our online training website for further videos)

DOASENSE Technology Animation
Divider

Listen to what opinion leaders think about DOASENSE's scientific education activities (symposia, etc.):
Divider
NOTE: DOASENSE(TM) products may not be available or approved in your country.


Copyright (c) 2016-2021 DOASENSE GmbH. All rights reserved.
Back to content